{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:47:47Z","timestamp":1791913667087,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":98,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-026-04461-2","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:25:44Z","timestamp":1783405544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clofazimine use for nontuberculous mycobacterial infections: 10-year experience in Belgium"],"prefix":"10.1186","volume":"26","author":[{"given":"Astrid","family":"Piot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Missault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8156-9420","authenticated-orcid":false,"given":"Yannick","family":"Vande Weygaerde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7918-7909","authenticated-orcid":false,"given":"Nityanand","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Van Bleyenbergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3230-0879","authenticated-orcid":false,"given":"Cedric","family":"Bosteels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Spriet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franky","family":"Buyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7242-0747","authenticated-orcid":false,"given":"Eva","family":"Van Braeckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2653-5885","authenticated-orcid":false,"given":"Natalie","family":"Lorent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"issue":"4","key":"4461_CR1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"DE Griffith","year":"2007","unstructured":"Griffith DE, et al. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367\u2013416.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"4461_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.ccm.2023.08.012","volume":"44","author":"DR Prevots","year":"2023","unstructured":"Prevots DR, et al. Global Epidemiology of Nontuberculous Mycobacterial Pulmonary Disease: A Review. Clin Chest Med. 2023;44(4):675\u2013721.","journal-title":"Clin Chest Med"},{"issue":"6","key":"4461_CR3","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1183\/09031936.00149212","volume":"42","author":"W Hoefsloot","year":"2013","unstructured":"Hoefsloot W, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013;42(6):1604\u201313.","journal-title":"Eur Respir J"},{"issue":"8","key":"4461_CR4","doi-asserted-by":"publisher","first-page":"e055672","DOI":"10.1136\/bmjopen-2021-055672","volume":"12","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, et al. Global prevalence of non-tuberculous mycobacteria in adults with non-cystic fibrosis bronchiectasis 2006\u20132021: a systematic review and meta-analysis. BMJ open. 2022;12(8):e055672.","journal-title":"BMJ open"},{"issue":"1","key":"4461_CR5","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s12931-022-02299-w","volume":"23","author":"R van der Laan","year":"2022","unstructured":"van der Laan R, Snabili\u00e9 A, Obradovic M. Meeting the challenges of NTM-PD from the perspective of the organism and the disease process: innovations in drug development and delivery. Respir Res. 2022;23(1):376.","journal-title":"Respir Res"},{"issue":"Suppl 2","key":"4461_CR6","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","volume":"72","author":"CS Haworth","year":"2017","unstructured":"Haworth CS, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(Suppl 2):ii1\u201364.","journal-title":"Thorax"},{"issue":"1","key":"4461_CR7","doi-asserted-by":"publisher","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","volume":"56","author":"CL Daley","year":"2020","unstructured":"Daley CL, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Eur Respir J. 2020;56(1):2000535.","journal-title":"Eur Respir J"},{"issue":"4","key":"4461_CR8","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.chest.2018.01.024","volume":"153","author":"R Diel","year":"2018","unstructured":"Diel R, et al. Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review. Chest. 2018;153(4):888\u2013921.","journal-title":"Chest"},{"issue":"5","key":"4461_CR9","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1093\/jac\/43.5.615","volume":"43","author":"VM Reddy","year":"1999","unstructured":"Reddy VM, O\u2019Sullivan JF, Gangadharam PR. Antimycobacterial activities of riminophenazines. J Antimicrob Chemother. 1999;43(5):615\u201323.","journal-title":"J Antimicrob Chemother"},{"key":"4461_CR10","unstructured":"Invaliditeitsverzekering R. v.Z.-e., Het Bijzonder Solidariteitsfonds (BSF)."},{"key":"4461_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ijid.2022.10.013","volume":"125","author":"VN Dahl","year":"2022","unstructured":"Dahl VN, et al. Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review. Int J Infect Dis. 2022;125:120\u201331.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"4461_CR12","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1186\/s12879-024-09965-y","volume":"24","author":"SJ Bents","year":"2024","unstructured":"Bents SJ, et al. Nontuberculous mycobacterial pulmonary disease (NTM PD) incidence trends in the United States, 2010\u20132019. BMC Infect Dis. 2024;24(1):1094.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"4461_CR13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/s12879-023-08468-6","volume":"23","author":"JE Marshall","year":"2023","unstructured":"Marshall JE, et al. Incidence of nontuberculous mycobacteria infections among persons with cystic fibrosis in the United States (2010\u20132019). BMC Infect Dis. 2023;23(1):489.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"4461_CR14","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","volume":"71","author":"RA Floto","year":"2016","unstructured":"Floto RA, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016;71(1):i1\u201322.","journal-title":"Thorax"},{"issue":"3","key":"4461_CR15","doi-asserted-by":"publisher","first-page":"e0115723","DOI":"10.1128\/aac.01157-23","volume":"68","author":"S Salillas","year":"2024","unstructured":"Salillas S, et al. Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model. Antimicrob Agents Chemother. 2024;68(3):e0115723.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"4461_CR16","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.chest.2023.11.038","volume":"165","author":"SMH Zweijpfenning","year":"2024","unstructured":"Zweijpfenning SMH, et al. Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment: Outcomes of a Randomized Trial. Chest. 2024;165(5):1082\u201392.","journal-title":"Chest"},{"key":"4461_CR17","doi-asserted-by":"publisher","first-page":"107718","DOI":"10.1016\/j.rmed.2024.107718","volume":"231","author":"F Watanabe","year":"2024","unstructured":"Watanabe F, et al. Clofazimine serum concentration and safety\/efficacy in nontuberculous mycobacterial pulmonary disease treatment. Respir Med. 2024;231:107718.","journal-title":"Respir Med"},{"issue":"4","key":"4461_CR18","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.chest.2017.04.175","volume":"152","author":"SL Martiniano","year":"2017","unstructured":"Martiniano SL, et al. Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection. Chest. 2017;152(4):800\u20139.","journal-title":"Chest"},{"issue":"7","key":"4461_CR19","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1016\/S1473-3099(21)00586-7","volume":"22","author":"C Lange","year":"2022","unstructured":"Lange C, et al. Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. Lancet Infect Dis. 2022;22(7):e178\u201390.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"4461_CR20","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1093\/jac\/dkae309","volume":"79","author":"R Stemkens","year":"2024","unstructured":"Stemkens R, et al. A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease. J Antimicrob Chemother. 2024;79(12):3100\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"4461_CR21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1513\/AnnalsATS.202412-1307OC","volume":"23","author":"J Kim","year":"2026","unstructured":"Kim J, et al. Adverse drug reactions during nontuberculous mycobacterial pulmonary disease treatment: a systematic review and meta-analysis. Ann Am Thorac Soc. 2026;23(2):292\u2013302.","journal-title":"Ann Am Thorac Soc"},{"issue":"11","key":"4461_CR22","doi-asserted-by":"publisher","first-page":"102823","DOI":"10.1016\/j.jiac.2025.102823","volume":"31","author":"F Watanabe","year":"2025","unstructured":"Watanabe F. Clinical considerations of the safety and efficacy of clofazimine in the treatment of nontuberculous mycobacterial disease. J Infect chemotherapy: official J Japan Soc Chemother. 2025;31(11):102823.","journal-title":"J Infect chemotherapy: official J Japan Soc Chemother"},{"key":"4461_CR23","unstructured":"Pharma N. Lamprene (clofazimine) capsules: highlights of prescribing information. 2019."},{"issue":"2","key":"4461_CR24","doi-asserted-by":"publisher","first-page":"107061","DOI":"10.1016\/j.ijantimicag.2023.107061","volume":"63","author":"S Bao","year":"2024","unstructured":"Bao S, et al. Efficacy of clofazimine-containing regimens for treatment of Mycobacterium avium complex\u2013pulmonary disease in patients unsuitable for standard treatment regimen. Int J Antimicrob Agents. 2024;63(2):107061.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"4461_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s44350-026-00012-1","volume":"2","author":"SJW Kang","year":"2026","unstructured":"Kang SJW, et al. Treatment outcomes and safety of clofazimine in nontuberculous mycobacterial pulmonary disease (NTM-PD). Mycobacteria. 2026;2(1):1.","journal-title":"Mycobacteria"},{"issue":"3","key":"4461_CR26","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jid.2017.09.031","volume":"138","author":"MD Murashov","year":"2018","unstructured":"Murashov MD, et al. The Physicochemical Basis of Clofazimine-Induced Skin Pigmentation. J Invest Dermatol. 2018;138(3):697\u2013703.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"4461_CR27","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","volume":"200","author":"P Nahid","year":"2019","unstructured":"Nahid P, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS\/CDC\/ERS\/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019;200(10):e93\u2013142.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"4461_CR28","doi-asserted-by":"publisher","first-page":"02687","DOI":"10.1128\/aac","volume":"65","author":"MT Abdelwahab","year":"2021","unstructured":"Abdelwahab MT, et al. Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis. Antimicrob Agents Chemother. 2021;65(7):02687\u201320. https:\/\/doi.org\/10.1128\/aac.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4461_CR29","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1186\/s12879-025-11605-y","volume":"25","author":"L Yao","year":"2025","unstructured":"Yao L, et al. Bedaquiline combined with clofazimine as salvage therapy for 11 patients with nontuberculous mycobacterial lung disease. BMC Infect Dis. 2025;25(1):1203.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"4461_CR30","doi-asserted-by":"publisher","first-page":"e01048","DOI":"10.1128\/spectrum.01048-23","volume":"11","author":"R Li","year":"2023","unstructured":"Li R, et al. Effects of Bedaquiline Combined with Fluoroquinolone and\/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study. Microbiol Spectr. 2023;11(4):e01048\u201323.","journal-title":"Microbiol Spectr"},{"key":"4461_CR31","doi-asserted-by":"crossref","unstructured":"Fares WH, et al. Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease. J of aerosol medicine and pulmonary drug delivery; 2025.","DOI":"10.1177\/19412711251389444"},{"issue":"2","key":"4461_CR32","doi-asserted-by":"publisher","first-page":"e0114422","DOI":"10.1128\/aac.01144-22","volume":"67","author":"M Kunkel","year":"2023","unstructured":"Kunkel M, et al. Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection. Antimicrob Agents Chemother. 2023;67(2):e0114422.","journal-title":"Antimicrob Agents Chemother"},{"key":"4461_CR33","unstructured":"EMA) EMA. EU\/3\/19\/2200 - orphan designation for treatment of nontuberculous mycobacterial lung disease. European Medicines Agency (EMA). 2023."},{"issue":"4","key":"4461_CR34","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1183\/09031936.00124614","volume":"45","author":"G G\u00fcnther","year":"2014","unstructured":"G\u00fcnther G, et al. Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey. Eur Respir J. 2014;45(4):1081\u20138.","journal-title":"Eur Respir J"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04461-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04461-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04461-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:01:53Z","timestamp":1791910913000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04461-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4461"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04461-2","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"5 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the respective ethics committees of UZ\/KU Leuven (MP 034837, S70431) and UZ Gent (S61188, S62926).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E.VB.\u2019s and N.L.\u2019s institution received financial support from Insmed for the conduct of clinical trials, consultancy, advisory boards and lectures in the field of NTM-PD. All other authors declare no conflicts of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"465"}}